Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pluristem Says Stem Cell Treatment Saves Patient

Published: Tuesday, August 07, 2012
Last Updated: Tuesday, August 07, 2012
Bookmark and Share
Company said that it has saved the life of a second patient with aplastic bone marrow, a condition in which the patient's bone marrow doesn't produce new blood cells.

In the most recent case, a woman who developed this condition following an unsuccessful bone-marrow transplant after being treated with radiation and chemotherapy for lymphoma experienced an improvement in her bone marrow and blood count following injection with Pluristem's cells, the company said.

In the other case earlier this year, Pluristem's stem cells were injected into a seven-year-old girl with aplastic anemia after two bone-marrow transplants failed to improve her condition. The stem-cell treatment improved her blood count enough for her to be released from hospital and ultimately saved her life, according to Pluristem and the girl's doctors.

Both patients were treated under Israel's compassionate-use clause at Hadassah Medical Center in Jerusalem.

Pluristem has applied for orphan drug status from the U.S. Food and Drug Administration for its treatment, based on stem cells derived from placenta. Orphan drug status, reserved for treatments of rare diseases, gives drug developers certain benefits, including government-subsidized research, exclusive marketing agreements and other financial incentives.

The Israel-based life-sciences company is working to use placenta-derived stem cells to treat a variety of other conditions, including radiation exposure, peripheral arterial disease, multiple sclerosis, and irritable bowel syndrome.

Clinical trials have recently shown the safety of using Pluristem's placenta-derived stem cells to treat peripheral arterial disease, it said. Pluristem's treatments have a large market potential because they are simple to administer, requiring only injections that can be given outside of a hospital setting, the company said.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pluristem Successfully Concludes Final Pre-Clinical Safety Studies with PLX-PAD in Preparation for Human Trials
Pluristem Therapeutics announce the successful conclusion of its pre-clinical studies utilizing PLX-PAD prior to the initiation of human clinical trials. PLX-PAD is Pluristem’s cellular product for the treatment of critical limb ischemia (CLI), the end phase of Peripheral Artery Disease (PAD).
Friday, September 12, 2008
Pluristem Certified as a Good Manufacturing Practices Site for the Manufacture of PLX cells for its Clinical Trials
The GMP certification has been approved for the purpose of manufacturing PLX cells which will be shipped to the EU for use in the Company’s upcoming clinical trials.
Thursday, June 26, 2008
Pluristem’s PLX Cells Show a Statistically Significant Advantage in a Pre-Clinical Study in the Multiple Sclerosis Model
PLX cells are mesenchymal stromal cells (MSCs) obtained from the placenta and expanded using Pluristem’s proprietary 3D PluriX™ technology.
Thursday, April 17, 2008
Pluristem’s Proprietary PLX Cells Demonstrate Promising Potential in Treating Autoimmune Disorders
The testing of PLX cells showed a reduction of TNF-a and interferon-? inflammatory cytokines that are involved in the pathogenesis of autoimmune disorders.
Thursday, November 29, 2007
Scientific News
Nanosensors Could Determine Tumours’ Ability to Remodel Tissue
Researchers design nanosensors that can profile tumours, focusing on protease levels.
1960s Antibiotics Show Promise for TB Therapy
Research suggests antibiotics introduced in 1963 to treat bacterial infections show promise for tuberculosis therapy.
Insight into Eye Diseases
Scientists recreate zebrafish cell regeneration from retinal stem cells in mice.
Analysing 10,000 Cells Simultaneously
New techniquethat traps 10,000 cells on a single chip has potential for cancer screening for individuals.
Studies Explore the Science of Cardiovascular Diseases
Two studies highlight how basic science research insights are key to future treatment breakthroughs.
Stem Cell ‘Heart Patch’ Almost Perfected
Scientists aiming to perfect and test 3D "heart patches" in animal model, last hurdle before human patients.
Using Stem Cells to Grow a 3D Lung-in-a-Dish
Researchers have created 3D lung-like tissue from lung-derived stem cells. The tissue can be used to study lung diseases.
MRI Guidance Aids Stem Cell Delivery
Scientists have delivered stem cells to the brain with unprecedented precision, infusing the cells under real-time MRI guidance.
Mechanisms of Parkinson’s Pathology
Defects that lead to cells’ failure to decommission faulty mitochondria cause nerve cells to die, triggering the symptoms of Parkinson’s disease.
Advanced Lymphoma in Remission After T-Cell Therapy
63% of trial participants who recieved two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!